Article

Plasma biomarkers predict amyloid conversion and cognitive decline in cognitively unimpaired adults

2026-07-10

Abstract excerpt

<title>Abstract</title> <p> <underline>Background:</underline> Alzheimer’s disease (AD) has a long preclinical phase. Development of disease-targeting therapies which may act in the early disease stage is dependent on the identification of at-risk individuals. We investigated whether plasma biomarkers phosphorylated-tau-217 (p-tau217), amyloid-β-42/40 (Aβ-42/40), neurofilament light (NfL) and glial fibrillary a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1f4b1728-490b-5398-a275-0e86c198fcc3
DOI: 10.21203/rs.3.rs-10226235/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Plasma biomarkers predict amyloid conversion and cognitive decline in cognitively unimpaired adultsDOI 10.21203/rs.3.rs-10226235/v1Read

APOE ε4 carriership status enhances age-related changes in Alzheimer’s disease plasma biomarkers concentrationsSemantic proximity Read

Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adultsSemantic proximity Read

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity Read

Genetic architecture of Alzheimer’s disease-related plasma biomarkersSemantic proximity Read

Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin studySemantic proximity Read

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s diseaseSemantic proximity Read

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measuresSemantic proximity Read

Cross-sectional study of plasma phosphorylated Tau 217 in persons without dementiaSemantic proximity Read

Clinicopathological and prognostic correlations of plasma biomarkers in neurodegenerative diseasesSemantic proximity Read

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity Read

Plasma biomarker levels and cognitive decline in a heterogenous community-based cohort with multiple comorbiditiesSemantic proximity Read